(Q44573297)

English

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

scientific article published on 4 September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

atrial fibrillation

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

object named as

Michael Wolzt

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Maria Wollbratt

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mia Svensson

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Karin Wåhlander

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Margaretha Grind

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Ulf G Eriksson

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

537-543

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

https://scigraph.springernature.com/pub.10.1007/s00228-003-0667-2

0 references

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibiti

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines a

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of stroke

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of stroke in patients with nonvalvular atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathobiology of thrombin in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombin and antithrombotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12955372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-003-0667-2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44573297&oldid=2143737045"